Revolution Medicines Inc. (42Z)
XDUS
Closed
Aug 24, 2026
Day's Range
176.9552 wk Range
30.00Overview - 42Z - Revolution Medicines Inc.
Key Statistics
Valuation
Enterprise Value
-225.04M
P/E (Trailing)
‪-30.11‬
PEG Ratio
‪-0.22‬
Price / Book
‪14.50‬
EV / EBITDA
‪0.20‬
Profitability
Return on Assets
‪-48.04%‬
Return on Equity
‪-69.34%‬
Ownership
Shares Outstanding
214.24M
Price stats
50-Day Avg
‪161.93‬
200-Day Avg
‪109.35‬
Peers - 42Z - Revolution Medicines Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- 42ZXDUSRevolution Medicines Inc.+82.66%52-week change-29.85P/E (Trailing)—Profit Margin
- 4E2XDUSRelmada Therapeutics Inc.+86.73%52-week change-2.70P/E (Trailing)—Profit Margin
- 3920XDUSSpyre Therapeutics, Inc.+84.37%52-week change-46.21P/E (Trailing)—Profit Margin
- 87EXDUSDianthus Therapeutics Inc.+78.20%52-week change-22.50P/E (Trailing)—Profit Margin
- 5NRAXDUSNanobiotix S.A. American Depositary Shares+77.55%52-week change—P/E (Trailing)—Profit Margin
- 5NRXDUSNanobiotix S.A.+77.54%52-week change—P/E (Trailing)—Profit Margin
- 7BGXDUSOncoinvent ASA+76.32%52-week change-0.06P/E (Trailing)—Profit Margin
Profile Summary - 42Z - Revolution Medicines Inc.
About
Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for cancers driven by the RAS protein, one of the most common cancer drivers affecting approximately 30% of human cancer diagnoses. Founded in 2014 and headquartered in Redwood City, California, the company applies…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
